Specialists address the intricate factors between comorbidities, efficacy, and tolerance, which influence their treatment approaches at the time of diagnosis. Mark Socinski, MD: Martin, we have seen ...
ECOG performance status is an important risk factor for early mortality in metastatic castration-resistant prostate cancer (mCRPC). Patients with metastatic castration-resistant prostate cancer (mCRPC ...
Chemoimmunotherapy was tested in patients with extensive-stage small cell lung cancer to determine its effect based on different performance statuses. Patients with extensive-stage small cell lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback